Employees: 2,870
Size Youcare Pharmaceutical (688658.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $674M, the 2979th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.17 on 18 Nov 2026.
Performance Over six months the shares fell 48.8%, against -6.0% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 7.3% over the last twelve months (peer median +11.6%); the operating margin is -13.2% (peer median 10.7%).
Valuation It trades at 24.9× forward earnings against a peer median of 17.0× (4th most expensive of 9).
Capital Return on invested capital runs 11.3 points below its cost of capital (6.9% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.36B | CN¥2.42B | CN¥3.75B | CN¥4.16B | CN¥4.50B |
| Revenue growth | — | -35% | -10% | -8% | — |
| Gross profit | CN¥1.37B | CN¥1.11B | CN¥2.06B | CN¥2.52B | CN¥2.83B |
| EBITDA | n/a | -CN¥25.3M | CN¥385M | CN¥379M | CN¥406M |
| Net income | -CN¥318M | -CN¥262M | CN¥124M | CN¥185M | CN¥335M |
| Free cash flow | -CN¥8.08M | CN¥209M | CN¥79.9M | CN¥288M | -CN¥668M |
| Capital expenditure | CN¥104M | CN¥135M | CN¥359M | CN¥497M | CN¥548M |
| Total debt | CN¥861M | CN¥738M | CN¥915M | CN¥678M | CN¥558M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688658.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.4% | -2.8% | 3rd lowest of 21 |
| 6-month return | -48.8% | -6.0% | lowest of 21 |
| Distance from 52-week high | -68.3% | -28.2% | lowest of 21 |
| Revenue growth (TTM) | -7.3% | +11.6% | 4th lowest of 18 |
| Operating margin | -13.2% | 10.7% | 3rd lowest of 18 |
| Forward P/E | 24.9× | 17.0× | 4th most expensive of 9 |
| ROIC minus cost of capital | -11.3 pp | -0.0 pp | 2nd lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 24.9× | n/a | n/a |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 10.1× | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 112.1× | 31.9% | +19.8% |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | n/a | -8.3% | -2.8% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 9.1× | n/a | n/a |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 18.0× | -1.6% | -1.8% |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | n/a | n/a | n/a |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | n/a | 25.2% | +10.3% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | n/a | 4.0% | +5.3% |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 32.2× | 27.1% | +31.4% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 79.7× | 9.1% | +7.9% |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | n/a | 36.3% | +16.2% |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 16.1× | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | n/a | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | n/a | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 13.7× | -4.8% | +6.4% |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | n/a | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |